Genetic Technologies : GTG Annual General Meeting Presentation
GTG.AX
ersonal use only
Annual General Meeting
Chief Executive Officer Presentation
November 24, 2021
Authorised by the Board of Directors of Genetic Technologies Limited
ASX: GTG
NASDAQ: GENE
ersonal use only
Notice: Forward looking statements
The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
ersonal use only
Unlocking personalised preventative health
Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.
We're transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment - where each person has the information, they need to manage their health according to their own risk.
Backed by over 20 years of experience, our doctors, scientist and technicians are translating genetic information into multi-tests that uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.
We're empowering physicians to improve health outcomes for people around the world. Tracking disease to its source. Enabling a new era of personalised medicine.
ersonal use only
Our Overview
01 02
Our Vision & Brand
Our Markets
Pillars
2021 Overview
Prioritising the
Where are
market entry strategy
we now
by region
03 04 05 06
Our Acquisition
Our Channels &
Our Portfolio &
Our Capabilities
Divisions
Innovation
EasyDNA - Building our
Focused on three distinct
Executing through cutting
Aligning our internal
Direct-to-Consumer growth
and target routes to market
edge innovation and 'game
capability aligned to
pathway
changing' partnerships
execution
4
Highlights and Results overview - Qtr. 1, 2021
ersonal use only A$'000
Receipts from Customers
850
89
Full Year FY21 Actual
Q1 FY22 Actual
Results as published on the ASX Monday October 4, 2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
Genetic Technologies Ltd. published this content on 23 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 November 2021 21:49:09 UTC.